131 related articles for article (PubMed ID: 8369230)
1. Haloperidol response and plasma catecholamines and their metabolites.
Green AI; Alam MY; Boshes RA; Waternaux C; Pappalardo KM; Fitzgibbon ME; Tsuang MT; Schildkraut JJ
Schizophr Res; 1993 Jun; 10(1):33-7. PubMed ID: 8369230
[TBL] [Abstract][Full Text] [Related]
2. Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
Chang WH; Chen TY; Lin SK; Lung FW; Lin WL; Hu WH; Yeh EK
Biol Psychiatry; 1990 Mar; 27(5):510-8. PubMed ID: 2310806
[TBL] [Abstract][Full Text] [Related]
3. Clozapine response and plasma catecholamines and their metabolites.
Green AI; Alam MY; Sobieraj JT; Pappalardo KM; Waternaux C; Salzman C; Schatzberg AF; Schildkraut JJ
Psychiatry Res; 1993 Feb; 46(2):139-49. PubMed ID: 8483973
[TBL] [Abstract][Full Text] [Related]
4. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
Brown AS; Gewirtz G; Harkavy-Friedman J; Cooper T; Brébion G; Amador XF; Malaspina D; Gorman JM
Neuropsychopharmacology; 1997 Nov; 17(5):317-25. PubMed ID: 9348547
[TBL] [Abstract][Full Text] [Related]
5. Plasma HVA in psychiatric patients: longitudinal studies.
Javaid JI; Sharma RP; Janicak PG; Davis JM
Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
[TBL] [Abstract][Full Text] [Related]
6. Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia.
Thibaut F; Ribeyre JM; Dourmap N; Ménard JF; Dollfus S; Petit M
Biol Psychiatry; 1998 Jan; 43(1):24-30. PubMed ID: 9442341
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
[TBL] [Abstract][Full Text] [Related]
8. Plasma catecholamine metabolites and early response to haloperidol.
Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
[TBL] [Abstract][Full Text] [Related]
9. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
Chang WH; Hwu HG; Chen TY; Lin SK; Lung FW; Chen H; Lin WL; Hu WH; Lin HN; Chien CP
Schizophr Res; 1993 Oct; 10(3):259-65. PubMed ID: 8260444
[TBL] [Abstract][Full Text] [Related]
10. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
[TBL] [Abstract][Full Text] [Related]
11. Correlates of rapid neuroleptic response in male patients with schizophrenia.
Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG
Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
[TBL] [Abstract][Full Text] [Related]
12. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period.
Sharma RP; Javaid JI; Davis JM; Janicak PG
Biol Psychiatry; 1998 Sep; 44(6):488-92. PubMed ID: 9777181
[TBL] [Abstract][Full Text] [Related]
14. A biomodal distribution of plasma HVA/MHPG in the psychoses.
Ottong SE; Garver DL
Psychiatry Res; 1997 Mar; 69(2-3):97-103. PubMed ID: 9109177
[TBL] [Abstract][Full Text] [Related]
15. Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
Bowers MB; Mazure CM; Nelson JC; Jatlow PI
Biol Psychiatry; 1992 Dec; 32(12):1102-7. PubMed ID: 1477190
[TBL] [Abstract][Full Text] [Related]
16. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
[TBL] [Abstract][Full Text] [Related]
17. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
18. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
19. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia.
Davidson M; Kahn RS; Stern RG; Hirschowitz J; Apter S; Knott P; Davis KL
Psychiatry Res; 1993 Feb; 46(2):151-63. PubMed ID: 8483974
[TBL] [Abstract][Full Text] [Related]
20. Predicting haloperidol treatment response in chronic schizophrenia.
van Kammen DP; Kelley ME; Yao JK; Gilbertson MW; Gurklis JA; Inosaka T; Saito H; Peters JL; Sato M
Psychiatry Res; 1996 Aug; 64(1):47-58. PubMed ID: 8888364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
